Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir

Journal of Hepatology

Volumn 63, Issue 1, 2015, Pages 20-29

  Menon, Rajeev M ^a   Badri, Prajakta S ^a   Wang, Tianli ^a   Polepally, Akshanth R ^a   Zha, Jiuhong ^a   Khatri, Amit ^a   Wang, Haoyu ^a   Hu, Beibei ^a   Coakley, Eoin P ^a   Podsadecki, Thomas J ^a   Awni, Walid M ^a   Dutta, Sandeep ^a  

^a ABBVIE INC   (United States)

Author keywords

Dasabuvir; Drug drug interactions; Hepatitis C virus; Ombitasvir; Paritaprevir; Ritonavir

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPRAZOLAM; AMLODIPINE; BUPRENORPHINE; CARBAMAZEPINE; DASABUVIR; DIGOXIN; DULOXETINE; ESCITALOPRAM; FUROSEMIDE; GEMFIBROZIL; KETOCONAZOLE; METHADONE; NALOXONE; NORETHISTERONE; OMBITASVIR; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PARITAPREVIR; PRAVASTATIN; RITONAVIR; ROSUVASTATIN; WARFARIN; ZOLPIDEM; ABT-267; ABT-333; ABT-450; ANILIDE; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; HEPATITIS C ANTIBODY; MACROCYCLIC COMPOUND; SULFONAMIDE; URACIL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CHRONIC HEPATITIS C; COMBINATION CHEMOTHERAPY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PRURITUS; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DRUG INTERACTION; HEPACIVIRUS; HEPATITIS C, CHRONIC; IMMUNOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; VIROLOGY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANILIDES; ANTIVIRAL AGENTS; CARBAMATES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; MACROCYCLIC COMPOUNDS; MALE; MIDDLE AGED; RITONAVIR; SULFONAMIDES; URACIL; YOUNG ADULT;

EID: 84928569640     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.01.026     Document Type: Article

References (21)

1. B.J. Veldt, E.J. Heathcote, H. Wedemeyer, J. Reichen, W.P. Hofmann, and S. Zeuzem Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis Ann Intern Med 147 2007 677 684
2. S. Bruno, A. Crosignani, C. Facciotto, S. Rossi, L. Roffi, and A. Redaelli Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study Hepatology 51 2010 2069 2076
3. V. Ng, and S. Saab Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C Clin Gastroenterol Hepatol 9 2011 923 930
4. L.I. Backus, D.B. Boothroyd, B.R. Phillips, P. Belperio, J. Halloran, and L.A. Mole A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C Clin Gastroenterol Hepatol 9 2011 509 516
5. D. Burger, D. Back, P. Buggisch, M. Buti, A. Craxí, and G. Foster Clinical management of drug-drug interactions in HCV therapy: challenges and solutions J Hepatol 58 2013 792 800
6. L. Serfaty Optimizing DAA management in daily practice Dig Liver Dis 45 2013 S318 S322
7. D. Back, and L. Else The importance of drug-drug interactions in the DAA era Dig Liver Dis 45 2013 S343 S348
8. P. Ferenci, D. Bernstein, J. Lalezari, D. Cohen, Y. Luo, and C. Cooper ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV N Engl J Med 370 2014 1983 1992
9. J.J. Feld, K.V. Kowdley, E. Coakley, S. Sigal, D.R. Nelson, and D. Crawford Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin N Engl J Med 370 2014 1594 1603
10. F. Poordad, C. Hezode, R. Trinh, K.V. Kowdley, S. Zeuzem, and K. Agarwal ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis N Engl J Med 370 2014 1973 1982
11. P. Andreone, M.G. Colombo, J.V. Enejosa, I. Koksal, P. Ferenci, and A. Maieron ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection Gastroenterology 147 2014 359 365
12. Bow DAJ, Liu J, Kavetskaia O, Menon R, de Morais SM, Nijsen M, et al. A mechanistic non-clinical assessment of drug-drug interactions (metabolism and transporters) with the hepatitis C virus (HCV) regimen: ABT-450/r, ombitasvir and dasabuvir. In: Poster presented at: 2014 American Association for the Study of Liver Diseases/European Association for the Study of the Liver Special Conference on Hepatitis C; September 12-13, 2014; New York, NY.
13. United States Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. Draft Guidance; February 2012. Available from: < http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf >.
14. European Medicines Agency. Guideline on the Investigation of Drug Interactions. CPMP/EWP/560/95/Rev. 1, 21 June 2012. Available from: < http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/07/WC500129606.pdf >.
15. F. Poordad, E. Lawitz, K.V. Kowdley, D.E. Cohen, T. Podsadecki, and S. Siggelkow Exploratory study of oral combination antiviral therapy for hepatitis C N Engl J Med 368 2013 45 53
16. K.V. Kowdley, E. Lawitz, F. Poordad, D.E. Cohen, D.R. Nelson, and S. Zeuzem Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1 N Engl J Med 370 2014 222 232
17. S. Mensing, A. Polepally, D. Konig, A. Khatri, W. Liu, and T. Podsadecki Population pharmacokinetics of ABT-450, ombitasvir, dasabuvir, ritonavir and ribavirin in subjects with HCV genotype 1 infection [abstract T-007] J Pharmacokinet Pharmacodyn 41 2014 S42
18. G.J. Sullivan, M. Rodrigues-Torres, E. Lawitz, F. Poordad, M. Kapoor, and A. Campbell ABT-267 combined with pegylated interferon alpha-2a/ribavirin in genotype 1 (GT1) HCV-infected treatment-naive subjects: 12 week antiviral and safety analysis [abstract 1210] J Hepatol 56 2012 S480
19. Gaultier IA, Cohen DE, Dumas EO, Larsen LM, Podsadecki TJ, Bernstein B. 12-Week efficacy and safety of ABT-072 or ABT-333 with pegylated interferon + ribavirin, following 3-day monotherapy in genotype 1 HCV-infected treatment-naïve subjects. In: Poster presented at: 21st Conference of the Asian Pacific Association for the Study of the Liver; February 17-20, 2011; Bangkok, Thailand. < http://www.natap.org/2011/APSL/APSL-02.htm >. Accessed October 17, 2014.
20. Rodriguez-Torres M, Lawitz E, Cohen D, Larsen LM, Menon R, Collins C, et al. Treatment-naïve, HCV genotype 1-infected subjects show significantly greater HCV RNA decreases when treated with 28 days of ABT-333 plus peginterferon and ribavirin compared to peginterferon and ribavirin alone [abstract LB6]. In: Presented at: The 60th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2009; October 30-November 3; Boston, MA.
21. M.P. Knadler, E. Lobo, J. Chappell, and R. Bergstrom Duloxetine: clinical pharmacokinetics and drug interactions Clin Pharmacokinet 50 2011 281 294